Role of dysregulated cholesterol metabolism in the pathogenesis of metabolic dysfunction-associated fatty liver disease

Role of dysregulated cholesterol metabolism in the pathogenesis of metabolic dysfunction-associated fatty liver disease - Association between metabolic dysfunction-associated fatty liver disease and dysregulated cholesterol metabolism

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060958

Enrollment

Registered

2026-03-17

Start date

2026-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic dysfunction-associated steatotic liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with suspected MASLD who are scheduled for liver biopsy

Exclusion criteria

Exclusion criteria: Presence of other liver diseases, including alcohol-related liver disease, drug-induced liver injury, viral hepatitis, autoimmune liver disease, and metabolic liver diseases Patients considered unsuitable for this study by the principal investigator or sub-investigator Patients who do not provide consent to participate in this study

Design outcomes

Primary

Measure	Time frame
Correlation of pathological findings in MASLD (MASLD activity score and fibrosis stage) with cholesterol crystallization and the distribution and phenotype of macrophages	—

Countries

Japan

Contacts

Public ContactKatsutoshi Sugimoto

Tokyo Medical University Department of Gastroenterology and Hepatology

sugimoto@tokyo-med.ac.jp03-3342-6111

Outcome results